Long-Term Partnership: Vector Science Embarks on Decade with LyoGenesis for Manufacturing Agreement

Vector Science and Therapeutics Corp. Announces New Agreement with LyoGenesis

Vector Science and Therapeutics Corp. has recently finalized an important agreement with LyoGenesis Holdings LLC, significantly enhancing its manufacturing capabilities for peptide-based pharmaceutical products. This long-term partnership aims to provide robust and reliable production capacity while adhering to stringent quality standards in the pharmaceutical industry.

The Agreement Details

On August 13, 2026, Vector's subsidiary, Vector Science and Therapeutics Operating Corp. (VST), entered into an amended and restated license and manufacturing agreement with LyoGenesis. This agreement, initially set for ten years, includes provisions for automatic annual renewals unless terminated earlier. The manufacturing operations will take place at LyoGenesis’s facility in Mequon, Wisconsin, ensuring compliance with Current Good Manufacturing Practices (cGMP).

Significance of the Partnership

This collaboration is poised to solidify Vector’s production processes, particularly for its proprietary lyophilized peptide products, which are integral to its pharmaceutical offerings. Each batch produced will be subjected to rigorous quality assurance checks conducted by Verlytix, an affiliate of Vector, before release, ensuring that all products meet the highest standards of efficacy and safety.

William Jackson, the CEO of Vector, expressed optimism about the agreement: “This amended agreement gives us a decade of secured, cGMP-compliant manufacturing capacity right here in the United States. A long-term, dependable supply chain is the foundation for scaling our peptide platform, and this agreement provides exactly that.”

Strategic Importance for Shareholders

Chairman Tommy Thompson highlighted the importance of this strategic move, stating, “Locking in a stable, decade-long manufacturing relationship with LyoGenesis reflects the kind of long-term planning our shareholders should expect from this team. A secure, U.S.-based supply chain is foundational to how we intend to scale.”

Moreover, the retention of title for all products upon delivery to VST underscores the security and reliability of this partnership.

About Vector Science and Therapeutics Corp.

Vector Science and Therapeutics Corp. positions itself as a leader in medical technology, focusing on advancing drug delivery systems and peptide manufacturing tailored for markets such as sports medicine, regenerative medicine, and pain management. Its wide-ranging product portfolio includes innovations in transdermal delivery, specialized catheter systems, and solutions for localized pain management.

The headquarters of Vector Science is located in Mequon, Wisconsin, and it is committed to driving forward the development of cutting-edge pharmaceuticals with a focus on precision and efficacy.

About LyoGenesis Holdings LLC

LyoGenesis Holdings LLC, also based in Wisconsin, specializes in the production and quality testing of pharmaceutical products under cGMP conditions. The collaboration with Vector will leverage LyoGenesis's existing capabilities to meet the growing demands of the pharmaceutical sector while ensuring quality throughout the manufacturing process.

Looking Ahead

The agreement is expected to have a significant positive impact on Vector’s operational capacity and its market reach as it aims to implement advanced medicines that can enhance patient outcomes in various therapeutic fields. With promising growth on the horizon, stakeholders and investors are likely to see the fruits of this strategic partnership in the years to come.